Conference presentation
LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
ContributorsMach, Nicolas; Fernandez, Eugenio; Vernet, Rémi; Von Rohr, Olivier; Urwyler, Muriel; Charrier, Emily Pauline; Belkouch, Marie-Claude; Saingier, Valentin; Courtout, Fabien; De Vito, Claudio; Rubin, Olivier; Ancrenaz, Virginie; Grogg, Julien; Renaux, Jessica; Gysel, Katrin; Müller, Gisela; Brezina, Tomas; Rordorf, Tamara; Joerger, Markus; Michielin, Olivier
Presented atESMO Congress 2023, Madrid, 20-24 octobre 2023
Publication date2023-10
NotePublished in : Annals of Oncology, Volume 34, Supplement 2, 2023, Page S1286.
Citation (ISO format)
MACH, Nicolas et al. LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy. In: ESMO Congress 2023. Madrid. 2023. doi: 10.1016/j.annonc.2023.10.040
Main files (1)
Presentation
Secondary files (1)
Identifiers
- PID : unige:180151
- DOI : 10.1016/j.annonc.2023.10.040
